ResultsIQ › Latest results › Windlas Biotech Limited
Windlas Biotech Limited Q2 FY27 earnings call summary
NSE: WINDLAS · BSE: 543329
Earnings call of 6 Nov 2026, summarised by AI from the filing.
Q2 FY27 revenue ₹264 cr, up 19% year-over-year, with ex-ESOP EBITDA at 13.7%; management gave no forward guidance.
Key takeaways
- Guidance No guidance given; management declined to guide CDMO momentum, export timing or trade generics recovery.
- Margin Ex-ESOP EBITDA 13.7% in Q2 FY27 versus 11-12% historically, with Plant 6 opex still to come in Q3.
- CDMO driver CDMO revenue ₹215 cr in Q2 FY27, up 34%, on more business in existing and new products with existing and new customers.
Windlas Biotech Limited Q2 FY27 results
As filed: Revenue ₹264 cr (+19% year on year), EBITDA ₹29.4 cr (+1% year on year), PAT ₹18.1 cr (0% year on year), EBITDA margin 11.1% (−194 bps).
The Q2 FY27 score, against the company's own trend, is for premium members.
Earlier results and the share price after them
- Q1 FY27: Revenue ₹248 cr (+18% year on year), EBITDA ₹26.7 cr (+3% year on year), PAT ₹17.7 cr (−2% year on year), EBITDA margin 10.8% (−162 bps). Score 36 of 100, Below trend. Revenue and profit growth were below the company's own trend; EBITDA growth was well below it. EBITDA margin fell 162 bps year on year. Revenue rose ₹38.1 cr on a year ago, more than the ₹35.0 cr it added the year before. Share price after the results: +29.4% in 30 days (Nifty 500: −3.2%).
- Q4 FY26: Revenue ₹239 cr (+17% year on year), EBITDA ₹25.3 cr (+1% year on year), PAT ₹16.0 cr (0% year on year), EBITDA margin 10.6% (−171 bps). Score 33 of 100, Below trend. Revenue and profit growth were below the company's own trend; EBITDA growth was well below it. EBITDA margin fell 171 bps year on year. Revenue rose ₹35.5 cr on a year ago, more than the ₹32.0 cr it added the year before. Share price after the results: +4.3% in 29 days (Nifty 500: +2.4%).
- Q3 FY26: Revenue ₹233 cr (+20% year on year), EBITDA ₹24.4 cr (+2% year on year), PAT ₹15.0 cr (−6% year on year), EBITDA margin 10.5% (−185 bps). Score 31 of 100, Below trend. Revenue growth was below the company's own trend; EBITDA and profit growth were well below it. EBITDA margin fell 185 bps year on year. Profit fell 17% from last quarter. Revenue rose ₹38.1 cr on a year ago, more than the ₹33.0 cr it added the year before. Share price after the results: −11.2% in 29 days (Nifty 500: −4.0%).
- Q2 FY26: Revenue ₹222 cr (+19% year on year), EBITDA ₹29.0 cr (+26% year on year), PAT ₹18.0 cr (+13% year on year), EBITDA margin 13.1% (+76 bps). Score 54 of 100, In line with trend. Revenue and profit growth were below the company's own trend; EBITDA growth was in line with it. EBITDA margin rose 76 bps year on year. Revenue rose ₹35.0 cr on a year ago, more than the ₹34.0 cr it added the year before. Share price after the results: −16.6% in 29 days (Nifty 500: +1.4%).
- Q1 FY26: Revenue ₹210 cr (+20% year on year), EBITDA ₹26.0 cr (+30% year on year), PAT ₹18.0 cr (+38% year on year), EBITDA margin 12.4% (+95 bps). Score 64 of 100, In line with trend. Revenue growth was below the company's own trend; EBITDA growth was in line with it; profit growth was above it. EBITDA margin rose 95 bps year on year. Revenue rose ₹35.0 cr on a year ago, more than the ₹30.0 cr it added the year before. Share price after the results: +5.9% in 30 days (Nifty 500: +2.1%).
- Q4 FY25: Revenue ₹203 cr (+19% year on year), EBITDA ₹25.0 cr (+9% year on year), PAT ₹16.0 cr (−6% year on year), EBITDA margin 12.3% (−114 bps). Score 32 of 100, Below trend. Revenue growth was below the company's own trend; EBITDA and profit growth were well below it. EBITDA margin fell 114 bps year on year. Revenue rose ₹32.0 cr on a year ago, more than the ₹30.0 cr it added the year before. Share price after the results: −8.9% in 29 days (Nifty 500: +2.0%).
- Q3 FY25: Revenue ₹195 cr (+20% year on year), EBITDA ₹24.0 cr (+20% year on year), PAT ₹16.0 cr (+7% year on year), EBITDA margin 12.3% (−4 bps). Score 34 of 100, Below trend. Revenue growth was below the company's own trend; EBITDA and profit growth were well below it. EBITDA margin was flat year on year. Revenue rose ₹33.0 cr on a year ago, against ₹42.0 cr the year before.
Past price moves after results do not indicate future moves. Not a recommendation.
Windlas Biotech Limited earnings call, investor presentation and press release summaries
- Q2 FY27: Earnings call (6 Nov 2026), Results deck (5 Nov 2026), Results press release (5 Nov 2026)
- Q1 FY27: Earnings call (11 Aug 2026), Results deck (10 Aug 2026), Results press release (10 Aug 2026)
- Q4 FY26: Earnings call (22 May 2026), Results deck (21 May 2026), Results press release (21 May 2026)
- Q3 FY26: Earnings call (6 Feb 2026), Results deck (5 Feb 2026), Results press release (5 Feb 2026)
- Q2 FY26: Earnings call (7 Nov 2025), Results deck (6 Nov 2025), Results press release (6 Nov 2025)
- Q1 FY26: Earnings call (13 Aug 2025), Results deck (12 Aug 2025), Results press release (12 Aug 2025)
- Q4 FY25: Earnings call (23 May 2025), Results deck (22 May 2025), Results press release (22 May 2025)
Figures from the company's filings with NSE and BSE. Not investment advice.